Cite
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups
MLA
Clorinda Schettino, et al. “Olaparib beyond Progression Compared with Platinum Chemotherapy after Secondary Cytoreductive Surgery in Patients with Recurrent Ovarian Cancer: Phase III Randomized, Open-Label MITO 35b Study, a Project of the MITO-MANGO Groups.” International Journal of Gynecologic Cancer, vol. 32, Mar. 2022, pp. 799–803. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8a7f6e30eb56d597fa47bdfe0d307e01&authtype=sso&custid=ns315887.
APA
Clorinda Schettino, Lucia Musacchio, Michele Bartoletti, Paolo Chiodini, Laura Arenare, Gustavo Baldassarre, Daniela Califano, Ettore Capoluongo, Maria Paola Costi, Maurizio D’Incalci, Sergio Marchini, Delia Mezzanzanica, Nicola Normanno, Stefania Scala, Stefano Greggi, Francesco Perrone, & Sandro Pignata. (2022). Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups. International Journal of Gynecologic Cancer, 32, 799–803.
Chicago
Clorinda Schettino, Lucia Musacchio, Michele Bartoletti, Paolo Chiodini, Laura Arenare, Gustavo Baldassarre, Daniela Califano, et al. 2022. “Olaparib beyond Progression Compared with Platinum Chemotherapy after Secondary Cytoreductive Surgery in Patients with Recurrent Ovarian Cancer: Phase III Randomized, Open-Label MITO 35b Study, a Project of the MITO-MANGO Groups.” International Journal of Gynecologic Cancer 32 (March): 799–803. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8a7f6e30eb56d597fa47bdfe0d307e01&authtype=sso&custid=ns315887.